Radiothérapie métabolique : quel rôle en 2001 ?
| Autor: | B. George, M.C. Douard, J.D. Rain |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Palliative care business.industry medicine.medical_treatment medicine.disease Surgery Metastasis Radiation therapy medicine.anatomical_structure Oncology Prostate Radionuclide therapy medicine Morphine Radiology Nuclear Medicine and imaging Radiology medicine.symptom Prospective cohort study Bone pain business medicine.drug |
| Zdroj: | Cancer/Radiothérapie. 6:188-200 |
| ISSN: | 1278-3218 |
| Popis: | Metabolic radiotherapy is a new therapy for management of bone pain in patients with bone metastatic prostate carcinoma. Strontium-89 and Samarium-153 concentrate in bone metastases and radiate them. A pain decrease is obtained in 60-70% of cases. Side effects are a significant hematological depression without great clinical consequences if good therapeutic indications are respected. Our multidisciplinary experience of these radionuclides in 54 performed treatments shows a rate of good responders of 66% with a rate of excellent results (total decrease of pain) in 47%. The therapeutic effectiveness is correlated with pain intensity measured by Visual Analogic Scale (VAS) and equivalent dose of morphine. Radionuclide therapy should be applied to patients as early as possible after establishment of bone metastases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect